ONC Stock: Price, Earnings History and SEC Filings
BeOne Medicines AG (ONC) last traded at $370.33, down 0.33% on the latest session and up 1.2% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $2.05 against an analyst estimate of $1.40, a beat of 46.4%.
$370.33 -0.33%
1 month+1.20%
52-week high$388.66
52-week low$253.95
Volume292,820
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ONC earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $2.05 | $1.40 | +46.43% |
| Mar 2026 | May 6, 2026 | $1.96 | $0.73 | +168.49% |
| Dec 2025 | Feb 26, 2026 | $0.58 | $1.60 | -63.75% |
| Sep 2025 | Nov 6, 2025 | $1.09 | $0.72 | +51.39% |
ONC beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for ONC
SEC filing data is not available right now. You can search for ONC on SEC EDGAR.
ONC news
- 3 Healthcare Stocks To Watch In October 2026Oct 24, 2026 · finance.yahoo.com
- BeOne Medicines (ONC) Could Be 13% Undervalued As ESMO Data Lifts The NarrativeOct 24, 2026 · finance.yahoo.com
- BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026Oct 24, 2026 · finance.yahoo.com
- BeOne Stock Tests Buy Zone With Visions Of 177% Earnings Growth. Watch This Clue.Oct 23, 2026 · finance.yahoo.com
- BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal CancerOct 23, 2026 · finance.yahoo.com
- BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5Oct 22, 2026 · finance.yahoo.com
- BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026Oct 19, 2026 · finance.yahoo.com
About BeOne Medicines AG
BeOne Medicines AG (ONC) is a US-listed public company on Nasdaq.